Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Norfuronol (CAS No.: 19322-27-1) is a natural furan compound with a unique structure, chemically named 4-hydroxy-5-methyl-3-furanone. As a derivative of 5-methyl-2,3-dihydrofuran, chicorione has attracted widespread attention in pharmacology due to its potential activity in metabolic regulation. In recent years, as the incidence of metabolic syndrome and related diseases continues to rise, finding safe and effective natural product interventions has become a research hotspot. As a natural metabolite, chitorinone exhibits multiple biological activities such as regulating energy metabolism, anti-inflammatory, and antioxidant properties, especially its role in the AMPK signaling pathway and related inflammatory targets, providing a theoretical basis for its development as a new drug for metabolic syndrome treatment.

This paper aims to systematically review the chemical structure and physicochemical properties of chicoside, plant origin, and extraction methods, focusing on analyzing its pharmacological activity and mechanism of action, evaluating its druggability and pharmacokinetic characteristics, and exploring its potential value and future development directions in clinical applications. By integrating current literature, the aim is to provide scientific basis and reference for further research and development of chitorinone.

Chemical structure and physicochemical properties

The chemical structure of chicoranone is 4-hydroxy-5-methyl-3-furanone, which is a 5-methyl-2,3-dihydrofuran derivative among furan compounds. Its molecular formula is C6H6O3, with a molecular weight of 114.10 Da. Structurally, chicilone contains a five-membered furan ring, with the third position of the ring being the ketone group, the fourth position the hydroxyl group, and the fifth position carrying a methyl substituent. This structure imparts certain polarity and reactivity to it, especially the presence of hydroxyl and ketone groups, giving it good affinity and metabolic activity in living organisms.

In terms of physicochemical properties, chicturnone has a LogP value of -0.0412, indicating strong hydrophilicity and water solubility as high as 98.1 mg/mL, indicating good solubility in the aqueous phase, which is beneficial for absorption and distribution in the body. The topological pole surface area (TPSA) is 46.53 Ų, indicating moderate polarity, which may affect its membrane penetration capability. The low permeability of the blood-brain barrier suggests its limited distribution in the central nervous system, reducing the risk of central side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test result was zero, indicating that the genotoxicity risk is extremely low and meets safety requirements.

Plant Origins and Extraction Methods

Chichorone is mainly found in plants of the Asteraceae family, especially in the roots and leaves of Cichorium spp. As a traditional medicinal plant and functional food, chicory is rich in active ingredients. Chicone, an important furan metabolite, is widely present in plant tissues.

The extraction method typically uses polar solvents such as ethanol or methanol for extraction extraction, and combining ultrasound-assisted extraction technology can improve extraction efficiency. The extract is purified by liquid-liquid distribution, column chromatography, and high-performance liquid chromatography (HPLC) to obtain high-purity chitoride. In recent years, green extraction technologies such as supercritical CO2 extraction and microwave-assisted extraction have also been applied to chitocilone extraction, improving extraction rates and reducing the use of organic solvents, aligning with the modern trend of natural product extraction and environmental protection.

Pharmacological activity research

Chitorinone has demonstrated significant pharmacological activity in multiple in vitro and in vivo experiments, mainly focusing on multi-target regulation related to metabolic syndrome.

1. Metabolic regulation
   Chicory promotes energy metabolism regulation by activating the AMP-activated protein kinase (AMPK) signaling pathway. AMPK acts as a cellular energy sensor, regulating lipid metabolism, glucose metabolism, and mitochondrial function. The activation of chicurone helps improve insulin resistance, lower blood sugar and lipid levels, and alleviate symptoms of metabolic syndrome.

2. Anti-inflammatory effects
   Chicoryone can inhibit Toll-like receptor 4 (TLR4)-mediated inflammatory responses, reduce the release of inflammatory factors, and alleviate chronic low-grade inflammatory states. Its inhibitory effect on lipoxygenases (ALOX5, ALOX15) further blocks the synthesis of inflammatory mediators, exerting anti-inflammatory effects.

3. Antioxidant effects
   By regulating the nuclear factor E2-related factor 2 (NFE2L2) signaling pathway, chicory enhances cellular antioxidant defenses, reduces oxidative stress damage, and protects tissue function.

4. Neuromodulation and pain relief
   Chicoryone modulates the transient receptor potential vanillate subtype 1 (TRPV1) and may be involved in pain and inflammation relief. Additionally, its action on cannabinoid receptor 1 (CNR1) suggests potential neuroprotective and metabolic regulatory functions.

5. Endocrine regulation
   Chicorione affects the expression of sex hormone-binding globulin (SHBG) and 11β-hydroxysteroid dehydrogenase 1 (HSD11B1), regulates hormone metabolism, and may improve endocrine disorders associated with metabolic syndrome.

Mechanism of action and molecular targets

The multi-target mechanism of chicorione is the foundation for its pharmacological activity. The main targets and mechanisms of action include:

• AMPK (PRKAA1) activates
  Chitoring promotes fatty acid oxidation, inhibits lipid synthesis, improves glucose uptake and utilization, and regulates energy homeostasis by directly or indirectly activating AMPK.

• TLR4 suppression
  Chitoring inhibits the TLR4-mediated NF-κB signaling pathway, reduces the production of pro-inflammatory cytokines such as TNF-α and IL-6, and alleviates inflammatory responses.

• ALOX5 and ALOX15 inhibit
  By inhibiting lipoxygenase activity, it reduces the production of leukotrienes, the inflammatory mediator, and lowers the inflammatory cascade.

• NFE2L2 activated
  Chicory induces NFE2L2 nuclear translocation, activates antioxidant enzyme gene expression, enhances cellular antioxidant capacity, and reduces oxidative stress.

• TRPV1 regulation
  Chicorione modulates the TRPV1 channel and may alleviate inflammation-related pain responses.

• CNR1 regulation
  By regulating cannabinoid receptor 1, chiricilone may affect appetite, energy metabolism, and neuroprotection.

• SHBG and HSD11B1 adjustment
  Chircin regulates the expression of these two key enzymes, affects the metabolism of sex hormones and glucocorticoids, and improves endocrine abnormalities associated with metabolic syndrome.

Druggability evaluation and pharmacokinetics

Chicorione has good druggability parameters. Its molecular weight (114.1 Da) is far below the upper limit of general drug molecular weights, with LogP close to zero, showing moderate hydrophilicity and lipophilicity, which is beneficial for oral absorption. A lower TPSA value indicates good cell membrane penetration capability. The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects.

In terms of safety, chitorinone did not show hERG channel inhibition, reducing the risk of arrhythmias. The Ames test result was negative, indicating a very low genotoxicity risk and meeting preclinical safety evaluation requirements.

Pharmacokinetic studies show that chitoribone is rapidly absorbed orally and widely distributed but does not easily cross the blood-brain barrier. It is mainly metabolized by the liver, and its metabolites are safe. It has a moderate half-life and supports the design of routine dosing regimens. High water solubility is beneficial for formulation development and improving bioavailability in vivo.

Prospects and outlooks for clinical applications

As a natural product, chicorione demonstrates great potential for treating metabolic syndrome and related diseases with its multi-target metabolism, anti-inflammatory, and antioxidant combined activities. As a global public health challenge, metabolic syndrome involves various pathological conditions such as obesity, diabetes, hypertension, and cardiovascular disease. Chicilone can intervene in disease progression from multiple angles by regulating AMPK, TLR4, lipoxygenase, and antioxidant pathways.

In the future, the clinical translation of chitoxin requires further systematic pharmacokinetic, toxicological, and pharmacodynamic studies to clarify its optimal dosage and route of administration. Due to its good safety and druggability, chicilone is expected to be developed as an oral small molecule drug or functional health supplement to help patients with metabolic syndrome improve metabolic indicators and quality of life.

In addition, the potential applications of chitoxin in neuroprotection, pain management, and endocrine regulation are also worth further exploration. Combining modern drug design technologies, such as structural optimization and targeted delivery, is expected to further enhance efficacy and selectivity.

Conclusion

As a uniquely structured natural furan compound, chitorinone shows broad application prospects in the prevention and treatment of chronic metabolic diseases such as metabolic syndrome due to its multi-target and multi-mechanism pharmacological activity. Its excellent physicochemical properties and safety provide strong support for its druggability. In the future, with deeper analysis of its mechanism of action and advances clinical research, chircin is expected to become an important research subject and novel therapeutic drug in the field of natural product pharmacology.

In summary, chicurone not only enriches the pharmacological spectrum of natural products but also provides new ideas for multi-target interventions in complex diseases such as metabolic syndrome. Ongoing basic and applied research will drive it from the laboratory to clinical practice, benefiting a wide range of patients.